Boothbay Fund Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Boothbay Fund Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-24,239	Closed	-$124K	–	1877
2021 Q2	$124K	Buy	+24,239	New	+$138K	﹤0.01%	1698
2021 Q1	–	Sell	-81,714	Closed	-$373K	–	1512
2020 Q4	$373K	Buy	+81,714	New	+$362K	0.01%	861
2020 Q3	–	Sell	-28,875	Closed	-$137K	–	1025
2020 Q2	$137K	Buy	28,875 +4,275	+17%	+$17.6K	0.01%	846
2020 Q1	$86K	Sell	24,600 -31,828	-56%	-$135K	0.01%	743
2019 Q4	$272K	Buy	+56,428	New	+$196K	0.02%	619

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's AMRX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2021, closing a stake of 24,239 shares — an estimated $124K sold.

Boothbay Fund Management first reported a position in AMRX in Q4 2019 and held it in 5 quarters. The position peaked at $373K in Q4 2020. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2021.

Boothbay Fund Management reported no remaining Amneal Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Boothbay Fund Management sold 24,239 Amneal Pharmaceuticals shares in Q3 2021, an estimated $124K.
Boothbay Fund Management first reported a position in Amneal Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Boothbay Fund Management's Amneal Pharmaceuticals position peaked at $373K in Q4 2020.
154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.